Intensive aerobic and muscle endurance exercise in patients with systemic sclerosis: a pilot study

BMC Research Notes

Annica Nordin²  Lena Björnådal²  Jenny Bergegård¹  Helene Alexanderson¹ 

[1] Department of Physical Therapy, Orthopedic/Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden;Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden

关键词: Interstitial lung disease;    Aerobic capacity;    Rehabilitation;    Physical exercise;    Systemic sclerosis;   

Others  :  1134497
DOI  :  10.1186/1756-0500-7-86

 received in 2013-05-30, accepted in 2014-01-23,  发布年份 2014

【 摘 要 】

Background

No previous studies have examined the effect of intensive exercise in systemic sclerosis patients with pulmonary impairment. The objective of this study was to examine the effect of an eight-week intensive aerobic exercise and muscle endurance training program for patients with systemic sclerosis with 50–100% of forced vital capacity.

Methods

A single-subject experimental design with repeated systematic measures during a six week A-phase (non-interventional baseline period) and an eight week B-phase (exercise intervention period) was used. Three women and one man with median age 66 years and median disease duration of 3.5 years completed aerobic exercise corresponding to 15 on the Borg RPE scale (strenuous) and muscular endurance training three times/week. Physical capacity (six-minute walk test), aerobic capacity (submaximal treadmill test) and muscle endurance in shoulder and hip flexion (Functional Index 2) were assessed every other week throughout the 14-week study. Activity limitation (Health Assessment Questionnaire), quality of life (Short Form 36), Raynaud, Fatigue and Global Health during the recent week (Visual Analogue Scales) were assessed at weeks 0, 6, 14.

Results

Three participants improved significantly in muscular endurance, and two participants improved significantly or clinically relevant in aerobic capacity. All other variables remained unchanged, except for a trend towards reduced fatigue.

Conclusions

This eight week exercise program was largely successful with positive effects on aerobic capacity and muscle endurance.

Trial registration

Clinicaltrials.gov Identifier: NCT01813578

【 授权许可】

   
2014 Alexanderson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Hinchcliff M, Varga J: Systemic sclerosis/Scleroderma: a treatable multisystem disease. Am Fam Physician 2010, 78:961-968.
• [2]Proudman SM, Stevens WM, Sahhar J, Celermajer D: Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007, 37:485.494.
• [3]Mouthon L, Berezné A, Brauner M, Kambouchner M, Guillevin L, Valeyre D: Interstitial lung disease in systemic sclerosis. Rev Mal Respir 2007, 24:1-11.
• [4]Hunzelmann N, Brinckmann J: What are the new milestones in the pathogenesis of systemic sclerosis. Ann Rheum Dis 2010, 69(Suppl 1):i52-i56.
• [5]Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y, et al.: Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR scleroderma trial and research group (EUSTAR) database. J Rheumatol 2010, 37:1488-1501.
• [6]Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA: Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology (Oxford) 2009, 48:165-169.
• [7]Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al.: Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the scleroderma lung study. Arthritis Rheum 2005, 52:592-600.
• [8]Steen VD: Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998, 17:48-54.
• [9]Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M, et al.: Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009, 61:1112-1160.
• [10]Oliveira NC, Dos Santos Sabbaq LM, De Sá Pinto AL, Borges CL, Lima FR: Aerobic exercise is safe and effective in systemic sclerosis. Int J Sports Med 2009, 30:728-732.
• [11]Pinto AL, Oliveira NC, Gaualano B, Christmann RB, Painelli VS, Artoli CG, et al.: Efficacy and safety of concurrent training in systemic sclerosis. J Strength Cond Res 2011, 25:1423-1428.
• [12]Maddali Bongi S, Del Rosso A, Galluccio F, Tai G, Sigismondi F, Passalacqua M, et al.: Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol 2009, 27(suppl 54):44-50.
• [13]Anonioli CM, Bua G, Frigè A, Prandini K, Radici S, Scarsi M, et al.: An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility. Clin Rheumatol 2009, 28:159-165.
• [14]Hurkmans E, Van Der Giesen FJ, Vliet Vlieland TPM, Schoones J, Van Den Ende EHCM: Dynamic exercise programs (aerobic capacity and and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev 2009., 7doi:10.1002/14651858.CD006853
• [15]Alexanderson H, Lundberg IE: Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheum 2012, 2012(24):201-207.
• [16]Markovitz GH, Cooper CB: Rehabilitation in non-COPD: mechanisms of exercise limitation and pulmonary rehabilitation for patients with pulmonary fibrosis/restrictive lung disease. Chron Resp Dis 2010, 7:47-60.
• [17]Minor MA, Johnson CJ: Reliability and validity of a submaximal treadmill test to estimate aerobic capacity in women with rheumatic disease. J Rheumatol 1996, 23:1517-1523.
• [18]American Thoracic Society Committee on Proficiency Standard for Clinical Pulmonary Function Laboratories: Guidelines for the six-minute walk test. Am Resp J Crit Care Med 2002, 166:111-117.
• [19]Buch MH, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells AU, et al.: Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007, 66:169-173.
• [20]Borg G: Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982, 14:377-381.
• [21]Borg G: Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970, 2:92-98.
• [22]Alexanderson H, Broman L, Tollbäck A, Lundberg IE, Stenström CH: Functional Index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2006, 55:114-122.
• [23]Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993, 36:729-740.
• [24]Ekdahl C, Eberhardt K, Andersson SI, Svensson B: Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988, 17:263-271.
• [25]Sullivan M, Karlsson J, Ware Je Jr, The Swedish SF-36 Health Survey: I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 1995, 41:1349-1358.
• [26]Zhan S, Ottenbacher KJ: Single subject research designs for disability research. Disabil Rehabil 2001, 23:1-8.
• [27]Backman CL, Harris SR, Chisholm JA, Monette AD: Single-Subject Research in Rehabilitation: a Review of Studies Using AB, Withdrawal, Multiple Baseline, and Alternating Treatments Designs. Arch Phys Med Rehabil 1997, 78:1145-1153.
• [28]Paulus HE, Egger MJ, Ward JR, Williams HJ: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Disease Ggroup. Arthritis Rheum 1990, 33:477-484.
• [29]Schoindre Y, Meune C, Dinh-Xuan A, Avouac J, Kahan A, Allanore Y: Lack of specificity of the 6. Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis. J Rheumatol 2009, 36:1481-1485.
• [30]Garin MC, Highland KB, Silver RM, Strange C: Limitations to the 6-minute walk test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma. J Rheumatol 2009, 36:330-336.
• [31]Clarke-Jenssen AC, Fredriksen PM, Lilleby V, Mengshoel AM: Effects of supervised aerobic exercise in patients with systemic lupus erythematosus: a pilot study. Arthritis Rheum 2005, 53:308-312.
• [32]Watson HR, Robb R, Belcher G, Belch JJ: Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 1999, 26:1734-1737.
• [33]Sandström S, Röstlund S, Alexanderson H: Improved muscle function following whole-body vibration exercise for patients with polymyositis and dermatomyositis. a pilot study. Ann Rheum Dis 2011, 70(Suppl. 3):776.
• [34]Saketkoo LA, Escorpizo R, Keen KJ, Fligelstone K, Distler O, EUSTAR: International Classification of Functioning, Disability and Health Core Set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. Rheumatology (Oxford) 2012, 51:2170-2176.